awmsg logo



linagliptin/metformin (Jentadueto®)


Reference No. 2446

Publication date:
14/08/2014


Appraisal information

linagliptin/metformin (Jentadueto®) 2.5 mg/1000 mg film-coated tablet
linagliptin/metformin (Jentadueto®) 2.5 mg/850 mg film-coated tablet


Company: Boehringer Ingelheim Ltd
BNF category: Endocrine system
NMG meeting date: 18/06/2014
AWMSG meeting date: 16/07/2014
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2114
Ministerial ratification: 13/08/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download